WHO
REGULATORY UPDATE
QCIL’s Artemether/Lumefantrine tablet prequalified
Published: 10/15/2026Detected: 9/5/2026
Summary preview
Adds QCIL’s artemether/lumefantrine 20 mg/120 mg tablets (MA211, Uganda) to the WHO Prequalification Programme list, following an assessment performed as a technology transfer product referencing Cipla’s MA064.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountOfficial Source Document Source Verified
Access the original document directly from WHO.